TRANSLATE

Welcome to Our Parkinson's Place


I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible. I have Parkinson's
diseases as well and thought it would be nice to have a place where
updated news is in one place. That is why I began this blog.
I am not responsible for it's contents, I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish. This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns. Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. Please No advertisers, and No Information about Herbal treatments. This is a free site for all.
Thank you.


Friday, April 21, 2017

Adamas to Give Presentations on Treatment for Involuntary Muscle Movements in Parkinson’s

BY DANIELA SEMEDO, PHD



Adamas Pharmaceuticals will make two presentations in Boston this month on ADS-5102 as a treatment for involuntary muscle movements associated with Parkinson’s disease.
ADS-5102, a high-dose amantadine therapy, decreases the duration, intensity and debility of the muscle movements, clinical trials have shown.
The problems, which range from slight hand tremors to uncontrollable upper body movements, stem from the long-term use of an amino-acid based therapy for Parkinson’s. That amino acid is levodopa, and the involuntary muscle movements are known as levodopa-induced dyskinesia (LID).
Adamas’ presentations on ADS-5102, also known as amantadine hydrochloride, will be at the 69th annual meeting of the American Academy of Neurology April 22-28 in Boston, the company said in a news release.
The presentations will cover two of the three Phase 3 clinical trials of ADS-5102 extended-release capsules as a treatment for LID in Parkinson’s, EASE LID and EASE LID 3.
EASE LID was a placebo-controlled randomized Phase 3 clinical trial (NCT02136914) that examined the effectiveness and safety of a 340-mg dose of ADS-5102 that patients received once a day, at bedtime, for 24 weeks.
The treatment led to an improvement in LID symptoms at 12 weeks, and the results held at 24 weeks, Adamas reported in April 2016.
EASE LID 3 was a placebo-controlled, randomized Phase 3 clinical trial (NCT02274766) that also looked at the effectiveness and safety of ADS-5102 in treating LID in Parkinson’s. Patients received one dose a day at bedtime.
In September 2016, Adamas reported that, after 12 weeks, EASE LID 3 had met its primary goal of reducing Parkinson’s patients’ scores on the Unified Dyskinesia Rating Scale. The drop in the scores indicated that ADS-5102 had decreased the duration, intensity, and disability associated with LID, the company said.
ADS-5102 also reduced Parkinson’s patients’ off-time, the period when Parkinson’s symptoms returned because the effects of levodopa treatment had worn off.
Another study, called EASED, was a placebo-controlled, randomized Phase 2/3 clinical trial (NCT01397422) that looked at the effectiveness and tolerability of three dose levels of ADS-5102 once a day in 83 Parkinson’s patients with LID.
More information about the ADS-5102 presentations can be found here, or by visiting the conference website.
In January the U.S. Food and Drug Administration (FDA) agreed to review Adamas’ New Drug Application (NDA) for ADS-5102 as an LID treatment in Parkinson’s.
https://parkinsonsnewstoday.com/2017/04/20/adamas-present-parkinsons-related-muscle-movement-therapy-boston-conference/

No comments:

Post a Comment